Prelude Therapeutics NASDAQ: PRLD outlined progress across three priority programs at a Chardan Capi

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nas

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure

The agreement supports the evaluation of Prelude’s clinical development candidate PRT13722, an oral

Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER

Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Surrozen (NASDAQ: SRZN - Get Free Report)

Shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD - Get Free Report) have been assigned an a

JP Morgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Over

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Na

"Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- bre

WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday&

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.14) per share which beat the ana

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While

ADAR1 Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, whic

US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Con

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.13) per share which beat the ana

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Pr

D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) w

Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmar

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a

Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Bioasis Technologies (OTCMKTS:BIOAF - Get

In lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 s

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Title: First-in-Class potent and selective oral KAT6A degrader development candidate, PRT13722, driv

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Respon

WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Aptorum Group (NASDAQ: APM - Get Free Report) and Prelude Therapeutics (NASDAQ: PRLD - Get Free Repo

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperf

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.20) per share which missed the a